Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETREMAC Trial: Personalized Treatment of High-risk Breast Cancer
NCT02624973Phase 2Active, not recruiting
- Sponsor
- Haukeland University Hospital
- Start
- Apr 2016
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib, olaparib, trastuzumab and pertuzumab in breast cancer (8 arms), sponsored by Haukeland University Hospital. Primary endpoint: Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing at 10 years. Started Apr 2016; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02624973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624973.